CoChat

Quantitative variability of 342 plasma proteins in a human twin population

Open access

The DOI matches its Crossref record; 82 of the 83 references it cites were found in a registry or an index.

Abstract

The degree and the origins of quantitative variability of most human plasma proteins are largely unknown. Because the twin study design provides a natural opportunity to estimate the relative contribution of heritability and environment to different traits in human population, we applied here the highly accurate and reproducible SWATH mass spectrometry technique to quantify 1,904 peptides defining 342 unique plasma proteins in 232 plasma samples collected longitudinally from pairs of monozygotic and dizygotic twins at intervals of 2–7 years, and proportioned the observed total quantitative variability to its root causes, genes, and environmental and longitudinal factors. The data indicate that different proteins show vastly different patterns of abundance variability among humans and that genetic control and longitudinal variation affect protein levels and biological processes to different degrees. The data further strongly suggest that the plasma concentrations of clinical biomarkers need to be calibrated against genetic and temporal factors. Moreover, we identified 13 cis‐ SNPs significantly influencing the level of specific plasma proteins. These results therefore have immediate implications for the effective design of blood‐based biomarker studies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15252/msb.20145728

Cites

82 of 82 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Experimental design The plasma proteomic survey of a longitudinal twin cohort was performed with SWATH-MS, an emerging mass spectrometry technique providing high quantitative accuracy and reproducibility. The observed overall variance of protein abundance was partitioned into four biological contributing factors (heritable, common environmental, individual environmental and longitudinally contributing factors) and unexplained effects using a linear mixed model.
Figure 1 Experimental design The plasma proteomic survey of a longitudinal twin cohort was performed with SWATH-MS, an emerging mass spectrometry technique providing high quantitative accuracy and reproducibility. The observed overall variance of protein abundance was partitioned into four biological contributing factors (heritable, common environmental, individual environmental and longitudinally contributing factors) and unexplained effects using a linear mixed model.CC BY · PubMed Central
Figure 2 Proteomic identification and reproducible quantification among the twin cohort A The establishment of a comprehensive, specific spectral library of human plasma proteome that is ready for SWATH-MS analysis. The reference spectra were generated a priori by extensive shotgun proteomic sequencing of fractionated plasma peptides and complemented with spectra of additional known plasma proteins (Farrah et al, 2011). B The coefficient of variance (CV) analysis at technical, whole-process experimental and cohort levels. C Heatmap of hierarchical clustering analysis of the protein vs. sample matrix indicates that plasma proteins were reproducibly quantified by SWATH-MS across the sample cohort. D The distribution of the fold changes of protein SWATH-MS intensities from their average abundance levels across the cohort is shown as box plots. Antithrombin III (ANT3) and vitamin D-binding protein (VTDB) are shown as examples of the most stable proteins, whereas apolipoprotein(a) (APOA) and serum amyloid A-1 protein (SAA1) are shown as examples of the most variable proteins. The red bars show the positions of the protein analytes whose measurement has been cleared or approved by FDA in human blood.
Figure 2 Proteomic identification and reproducible quantification among the twin cohort A The establishment of a comprehensive, specific spectral library of human plasma proteome that is ready for SWATH-MS analysis. The reference spectra were generated a priori by extensive shotgun proteomic sequencing of fractionated plasma peptides and complemented with spectra of additional known plasma proteins (Farrah et al, 2011). B The coefficient of variance (CV) analysis at technical, whole-process experimental and cohort levels. C Heatmap of hierarchical clustering analysis of the protein vs. sample matrix indicates that plasma proteins were reproducibly quantified by SWATH-MS across the sample cohort. D The distribution of the fold changes of protein SWATH-MS intensities from their average abundance levels across the cohort is shown as box plots. Antithrombin III (ANT3) and vitamin D-binding protein (VTDB) are shown as examples of the most stable proteins, whereas apolipoprotein(a) (APOA) and serum amyloid A-1 protein (SAA1) are shown as examples of the most variable proteins. The red bars show the positions of the protein analytes whose measurement has been cleared or approved by FDA in human blood.CC BY · PubMed Central
Figure 3 Dissection of the plasma protein-level variability A Histograms of contribution percentage of each biological component (red: heritability; light blue: common environment; dark blue: individual environment; yellow: longitudinal effects; gray: unexplained fraction) determined by a linear mixed model based on the longitudinal twin design. Selected protein names are shown for those clinically assayed proteins with the most heritable levels, for example, APOA, plasma protease C1 inhibitor (IC1), complement C4-A (CO4A), fibrinogen alpha chain (FIBA) and pancreatic triacylglycerol lipase (LIPP), and for the most variable proteins among the cohort, for example, SAA1, APOA, pregnancy zone protein (PZP), trifunctional enzyme subunit alpha (ECHA) and C-reactive protein (CRP). B Examples of protein abundance correlations between MZ and DZ pairs. Fibrinogen beta chain (FIBB), Serum paraoxonase/arylesterase 1 (PON1).
Figure 3 Dissection of the plasma protein-level variability A Histograms of contribution percentage of each biological component (red: heritability; light blue: common environment; dark blue: individual environment; yellow: longitudinal effects; gray: unexplained fraction) determined by a linear mixed model based on the longitudinal twin design. Selected protein names are shown for those clinically assayed proteins with the most heritable levels, for example, APOA, plasma protease C1 inhibitor (IC1), complement C4-A (CO4A), fibrinogen alpha chain (FIBA) and pancreatic triacylglycerol lipase (LIPP), and for the most variable proteins among the cohort, for example, SAA1, APOA, pregnancy zone protein (PZP), trifunctional enzyme subunit alpha (ECHA) and C-reactive protein (CRP). B Examples of protein abundance correlations between MZ and DZ pairs. Fibrinogen beta chain (FIBB), Serum paraoxonase/arylesterase 1 (PON1).CC BY · PubMed Central
Figure 4 Biological and biomedical insights derived from twin proteomic data A Enrichment analysis of pathways and biological processes regulated by the four biological components was performed. The results were compiled into clusters according to the functional annotation of proteins. B Low correlation between plasma protein levels extracted from PeptideAtlas (www.peptideatlas.org) and their heritability contributing percentages in biological variance indicating the lack of an abundance bias. In contrast to that, concentration variability of more abundant proteins is generally less affected by longitudinal factors. The light red dashed line indicates the protein concentration of 1 μg/ml, which separates the proteins into two abundance classes. C Comparison of high-density lipoproteins (HDLs) and other proteins, using the heritability contributing percentages in biological variance of the plasma protein levels. D Comparison of heritability contributing percentages in biological variance between those proteins annotated as glycoproteins and other proteins. P-values are determined by Wilcoxon rank-sum test. E Decreasing trend of heritability control in plasma protein levels along with 5-year longitudinal process. F Clinically assayed proteins generally show lower quantitative variability compared to other plasma proteins with few exceptions, for example, CRP and APOA. G Examples of previously reported protein biomarker candidates, the plasma abundance levels of which were highly regulated by longitudinal effects. These include hexokinase-1 (HXK1), triosephosphate isomerase (TPIS), 14-3-3 protein zeta/delta (1433Z), platelet basic protein (CXCL7), monocyte differentiation antigen CD14 (CD14), biotinidase (BTD), serotransferrin (TRFE) and thyroxine-binding globulin (THBG). Data information: P-values are determined by Wilcoxon rank-sum test.
Figure 4 Biological and biomedical insights derived from twin proteomic data A Enrichment analysis of pathways and biological processes regulated by the four biological components was performed. The results were compiled into clusters according to the functional annotation of proteins. B Low correlation between plasma protein levels extracted from PeptideAtlas (www.peptideatlas.org) and their heritability contributing percentages in biological variance indicating the lack of an abundance bias. In contrast to that, concentration variability of more abundant proteins is generally less affected by longitudinal factors. The light red dashed line indicates the protein concentration of 1 μg/ml, which separates the proteins into two abundance classes. C Comparison of high-density lipoproteins (HDLs) and other proteins, using the heritability contributing percentages in biological variance of the plasma protein levels. D Comparison of heritability contributing percentages in biological variance between those proteins annotated as glycoproteins and other proteins. P-values are determined by Wilcoxon rank-sum test. E Decreasing trend of heritability control in plasma protein levels along with 5-year longitudinal process. F Clinically assayed proteins generally show lower quantitative variability compared to other plasma proteins with few exceptions, for example, CRP and APOA. G Examples of previously reported protein biomarker candidates, the plasma abundance levels of which were highly regulated by longitudinal effects. These include hexokinase-1 (HXK1), triosephosphate isomerase (TPIS), 14-3-3 protein zeta/delta (1433Z), platelet basic protein (CXCL7), monocyte differentiation antigen CD14 (CD14), biotinidase (BTD), serotransferrin (TRFE) and thyroxine-binding globulin (THBG). Data information: P-values are determined by Wilcoxon rank-sum test.CC BY · PubMed Central
Figure 5 pQTL discovery in human plasma A Manhattan plot of the best P-value per gene, highlighting the 13 statistically significant pQTL associations. The asterisks indicate that the corresponding eQTLs were found in human tissues. The cutoff of the P-value is 6.166e-3. B Examples of pQTLs: plasma protein levels among the cohort of four proteins associated with innate immune response distributed by distinct genotypes of the SNPs (see Supplementary Table S3 for all abbreviations of protein names).
Figure 5 pQTL discovery in human plasma A Manhattan plot of the best P-value per gene, highlighting the 13 statistically significant pQTL associations. The asterisks indicate that the corresponding eQTLs were found in human tissues. The cutoff of the P-value is 6.166e-3. B Examples of pQTLs: plasma protein levels among the cohort of four proteins associated with innate immune response distributed by distinct genotypes of the SNPs (see Supplementary Table S3 for all abbreviations of protein names).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 82 references

Cited by

Items 301–333 of 333

Metadata

Authors
Liu, Y., Buil, A., Collins, B. C., Gillet, L. C., Blum, L. C., Cheng, L., Vitek, O., Mouritsen, J., Lachance, G., Spector, T. D., Dermitzakis, E. T., & Aebersold, R.
Affiliations
  • ETH Zurich (CH)
  • University of Geneva (CH)
  • Purdue University West Lafayette (US)
  • King's College London (GB)
  • University of Zurich (CH)
Corresponding author
  • Liu, Yansheng
  • Aebersold, Ruedi
Venue
Molecular Systems Biology
Published
2015-02-01
Volume
11
Issue
2
Pages
786-786
ISSN
1744-4292 (ISSN-L)
OpenAlex
W2142205442
Cited by
328
References
83
Citations by year
2026: 9 · 2025: 13 · 2024: 24 · 2023: 27 · 2022: 33 · 2021: 36 · 2020: 28 · 2019: 43 · 2018: 38 · 2017: 38 · 2016: 23 · 2015: 16
FWCI
26.35
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Systems Biology (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Archive ouverte UNIGE (University of Geneva) (publishedVersion, other-oa)
  • Repository for Publications and Research Data (ETH Zurich) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Research Portal (Queen's University Belfast) (submittedVersion, cc-by)
  • Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
  • ETH Zürich Research Collection (cc-by)
Funders
  • Swiss National Science Foundation (310030B_147086)
  • SystemsX.ch
  • European Research Council (ERC‐2008‐AdG 233226)
  • PRIME‐XS
  • Wellcome Trust and EC's Seventh Framework Programme (FP7/2007‐2013)
  • National Institute for Health Research‐funded BioResource
  • Clinical Research Facility and Biomedical Research Centre
  • St Thomas' NHS Foundation Trust
  • King's College London
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
  • Physical Sciences › Chemistry › Spectroscopy › Advanced Proteomics Techniques and Applications
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolomics and Mass Spectrometry Studies
Keywords
plasma proteins, monozygotic twins, dizygotic twins, heritability, environmental effects, longitudinal variation, clinical biomarkers, blood-based biomarkers, SWATH mass spectrometry
MeSH terms
Adult, Aged, Blood Proteins, Evaluation Studies as Topic, Female, Genetic Markers, Humans, Longitudinal Studies, Middle Aged, Twins, Dizygotic, Twins, Monozygotic, Linear Models, Computational Biology, Polymorphism, Single Nucleotide, Databases, Genetic, Quantitative Trait Loci, Proteomics, White People

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.